Pfizer earnings projections disappoint
Pfizer said its 2006 revenues will be comparable to 2005, as growth of current and new products offsets revenue declines from loss of exclusivity and adverse foreign exchange.
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.